Altered expression of costimulatory molecules in Behçet's disease according to clinical activity

British Journal of Dermatology

Volumn 164, Issue 6, 2011, Pages 1285-1291

  Sim, J H ^a   Park, M J ^a   Park, S ^a   Lee, E S ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IONOMYCIN; MESSENGER RNA; PHORBOL MYRISTATE; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; APHTHOUS ULCER; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD274; ANTIGENS, CD80; ANTIGENS, CD86; BEHCET SYNDROME; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; CTLA-4 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 79957610679     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10274.x     Document Type: Article

References (33)

1. Sakane T, Takeno M, Suzuki N, Inaba G,. Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. Mendes D, Correia M, Barbedo M, et al. Behçet's disease-a contemporary review. J Autoimmun 2009; 32: 178-88.
3. Fife BT, Bluestone JA,. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-82.
4. Scalapino KJ, Daikh DI,. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223: 143-55. (Pubitemid 351986184)
5. Walunas TL, Bakker CY, Bluestone JA,. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-50. (Pubitemid 26192364)
6. Salomon B, Bluestone JA,. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-52. (Pubitemid 32368035)
7. Slavik JM, Hutchcroft JE, Bierer BE,. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999; 19: 1-24. (Pubitemid 29248709)
8. Jury EC, Flores-Borja F, Kalsi HS, et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol 2010; 40: 569-78.
9. Steiner K, Moosig F, Csernok E, et al. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 2001; 126: 143-50. (Pubitemid 32989504)
10. Wang XB, Kakoulidou M, Giscombe R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002; 130: 224-32. (Pubitemid 35240010)
11. Gunesacar R, Erken E, Bozkurt B, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet 2007; 34: 45-9. (Pubitemid 46232341)
12. Park KS, Baek JA, Do JE, et al. CTLA-4 gene polymorphisms and soluble CTLA-4 protein in Behçet's disease. Tissue Antigens 2009; 74: 222-7.
13. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
14. Kitazawa Y, Fujino M, Wang Q, et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007; 83: 774-82. (Pubitemid 46569197)
15. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-51. (Pubitemid 29428807)
16. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-9. (Pubitemid 36870186)
17. Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706-16. (Pubitemid 37337136)
18. Dong H, Zhu G, Tamada K, et al. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004; 20: 327-36. (Pubitemid 38388234)
19. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PD-L1 mediated regulation of autoimmune diabetes. Clin Immunol 2007; 125: 16-25. (Pubitemid 47376921)
20. Alpsoy E, Zouboulis CC, Ehrlich GE,. Mucocutaneous lesions of Behçet's disease. Yonsei Med J 2007; 48: 573-85.
21. Yi SW, Kim EH, Kang HY, et al. Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis. Yonsei Med J 2007; 48: 601-8. (Pubitemid 47496721)
22. Saverino D, Brizzolara R, Simone R, et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007; 123: 190-8. (Pubitemid 46590071)
23. Liu MF, Wang CR, Chen PC, Fung LL,. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 2003; 57: 568-72.
24. Fernandez-Blanco L, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A,. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum 2004; 50: 328-9. (Pubitemid 38084319)
25. Kula D, Bednarczuk T, Jurecka-Lubieniecka B, et al. Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1 07. Thyroid 2006; 16: 447-53.
26. Bluestone JA, St Clair EW, Turka LA,. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006; 24: 233-8.
27. Racke MK, Scott DE, Quigley L, et al. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995; 96: 2195-203.
28. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145-55.
29. Johansson SM, Admyre C, Scheynius A, Gabrielsson S,. Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes. Immunology 2008; 123: 491-9. (Pubitemid 351280963)
30. Grant V, King AE, Faccenda E, Kelly RW,. PGE/cAMP and GM-CSF synergise to induce a pro-tolerance cytokine profile in monocytic cell lines. Biochem Biophys Res Commun 2005; 331: 187-93. (Pubitemid 40545160)
31. Reynoso ED, Elpek KG, Francisco L, et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol 2009; 182: 2102-12.
32. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-29.
33. Ding H, Wu X, Wu J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS costimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol 2006; 118: 258-67. (Pubitemid 43199665)